|
1
|
Jaquet K, Krause KT, Denschel J, et al:
Reduction of myocardial scar size after implantation of mesenchymal
stem cells in rats: what is the mechanism? Stem Cells Dev.
14:299–309. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ohnishi S, Sumiyoshi H, Kitamura S and
Nagaya N: Mesenchymal stem cells attenuate cardiac fibroblast
proliferation and collagen synthesis through paracrine actions.
FEBS Lett. 581:3961–3966. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Song SW, Chang W, Song BW, et al:
Integrin-linked kinase is required in hypoxic mesenchymal stem
cells for strengthening cell adhesion to ischemic myocardium. Stem
Cells. 27:1358–1365. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Iwase T, Nagaya N, Fujii T, et al:
Comparison of angiogenic potency between mesenchymal stem cells and
mononuclear cells in a rat model of hindlimb ischemia. Cardiovasc
Res. 66:543–551. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chen K, Chen J, Li D, Zhang X and Mehta
JL: Angiotensin II regulation of collagen type I expression in
cardiac fibroblasts: modulation by PPAR-gamma ligand pioglitazone.
Hypertension. 44:655–661. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Frangogiannis NG, Dewald O, Xia Y, et al:
Critical role of monocyte chemoattractant protein-1/cc chemokine
ligand 2 in the pathogenesis of ischemic cardiomyopathy.
Circulation. 115:584–592. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li W, Ma N, Ong LL, et al: Bcl-2
engineered MSCs inhibited apoptosis and improved heart function.
Stem Cells. 25:2118–2127. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Goldsmith EC, Hoffman A, Morales MO, et
al: Organization of fibroblasts in the heart. Dev Dyn. 230:787–794.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Weber KT: Fibrosis in hypertensive heart
disease: focus on cardiac fibroblasts. J Hypertens. 22:47–50. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Brown RD, Ambler SK, Mitchell MD and Long
CS: The cardiac fibroblast: therapeutic target in myocardial
remodeling and failure. Annu Rev Pharmacol Toxicol. 45:657–687.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Camelliti P, Borg TK and Kohl P:
Structural and functional characterisation of cardiac fibroblasts.
Cardiovasc Res. 65:40–51. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dai W, Hale SL and Kloner RA: Role of a
paracrine action of mesenchymal stem cells in the improvement of
left ventricular function after coronary artery occlusion in rats.
Regen Med. 2:63–68. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li L, Zhang S, Zhang Y, Yu B, Xu Y and
Guan Z: Paracrine action mediate the antifibrotic effect of
transplanted mesenchymal stem cells in a rat model of global heart
failure. Mol Biol Rep. 36:725–731. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xu RX, Chen X, Chen JH, Han Y and Han BM:
Mesenchymal stem cells promote cardiomyocyte hypertrophy in vitro
through hypoxia-induced paracrine mechanisms. Clin Exp Pharmacol
Physiol. 36:176–180. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Attwell S, Mills J, Troussard A, Wu C and
Dedhar S: Integration of cell attachment, cytoskeletal
localization, and signaling by integrin-linked kinase (ILK),
CH-ILKBP, and the tumor suppressor PTEN. Mol Biol Cell.
14:4813–4825. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tan C, Mui A and Dedhar S: Integrin-linked
kinase regulates inducible nitric oxide synthase and
cyclooxygenase-2 expression in an NF-kappa B-dependent manner. J
Biol Chem. 277:3109–3116. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Troussard AA, McDonald PC, Wederell ED, et
al: Preferential dependence of breast cancer cells versus normal
cells on integrin-linked kinase for protein kinase B/Akt activation
and cell survival. Cancer Res. 66:393–403. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ding L, Dong L, Chen X, et al: Increased
expression of integrin-linked kinase attenuates left ventricular
remodeling and improves cardiac function after myocardial
infarction. Circulation. 120:764–773. 2009. View Article : Google Scholar
|
|
19
|
Gabbiani G: Evolution and clinical
implications of the myofibroblast concept. Cardiovasc Res.
38:545–548. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Petrov VV, Fagard RH and Lijnen PJ:
Stimulation of collagen production by transforming growth
factor-beta 1 during differentiation of cardiac fibroblasts to
myofibroblasts. Hypertension. 39:258–263. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen MM, Lam A, Abraham JA, Schreiner GF
and Joly AH: CTGF expression is induced by TGF-beta in cardiac
fibroblasts and cardiac myocytes: A potential role in heart
fibrosis. J Mol Cell Cardiol. 32:1805–1819. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Frazier K, Williams S, Kothapalli D,
Klapper H and Grotendorst GR: Stimulation of fibroblast cell
growth, matrix production, and granulation tissue formation by
connective tissue growth factor. J Invest Dermatol. 107:404–411.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Igarashi A, Okochi H, Bradham DM and
Grotendorst GR: Regulation of connective tissue growth factor gene
expression in human skin fibroblasts and during wound repair. Mol
Biol Cell. 4:637–645. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Olson MW, Gervasi DC, Mobashery S and
Fridman R: Kinetic analysis of the binding of human matrix
metalloproteinase-2 and -9 to tissue inhibitor of metalloproteinase
(TIMP)-1 and TIMP-2. J Biol Chem. 272:29975–29983. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Vanhoutte D, Schellings M, Pinto Y and
Heymans S: Relevance of matrix metalloproteinases and their
inhibitors after myocardial infarction: A temporal and spatial
window. Cardiovasc Res. 69:604–613. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Brew K, Dinakarpandian D and Nagase H:
Tissue inhibitors of metalloproteinases: evolution, structure and
function. Biochim Biophys Acta. 1477:267–283. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Menon B, Singh M and Singh K: Matrix
metalloproteinases mediate beta-adrenergic receptor-stimulated
apoptosis in adult rat ventricular myocytes. Am J Physiol Cell
Physiol. 289:C168–C176. 2005. View Article : Google Scholar
|
|
28
|
Goldberg GI, Marmer BL, Grant GA, Eisen
AZ, Wilhelm S and He CS: Human 72-kilodalton type IV collagenase
forms a complex with a tissue inhibitor of metalloproteases
designated TIMP-2. Proc Natl Acad Sci USA. 86:8207–8211. 1989.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Goldberg GI, Strongin A, Collier IE,
Genrich LT and Marmer BL: Interaction of 92-kDa type IV collagenase
with the tissue inhibitor of metalloproteinases prevents
dimerization, complex formation with interstitial collagenase, and
activation of the proenzyme with stromelysin. J Biol Chem.
267:4583–4591. 1992.
|
|
30
|
Brown RD, Jones GM, Laird RE, Hudson P and
Long CS: Cytokines regulate matrix metalloproteinases and migration
in cardiac fibroblasts. Biochem Biophys Res Commun. 362:200–205.
2007. View Article : Google Scholar : PubMed/NCBI
|
